5 Best Performing Stocks of Q1 2026 to Watch for Q2
This article lists the top 5 best-performing stocks of Q1 2026, focusing on one specific company in detail. Enliven Therapeutics, Inc. (NASDAQ: ELVN) saw a 152.25% gain, with analysts increasing price targets after a competitor acquisition and positive Phase 1b data for its ELVN-001 drug candidate for chronic myeloid leukemia. The piece also includes a speculative advertisement about an AI investment opportunity.
25,000-share resale via Jefferies — Enliven Therapeutics (NASDAQ: ELVN)
Enliven Therapeutics (NASDAQ: ELVN) submitted a Form 144 to propose the sale of 25,000 common shares through Jefferies LLC, valued at $914,750, with an entry date of March 31, 2026. The filing also detailed several past sale dispositions by Joseph Lyssikatos, a beneficial owner, including transactions in January and February 2026. A Form 144 is a notice of intent to sell restricted securities and does not guarantee the completion of the sale.
[144] Enliven Therapeutics, Inc. SEC Filing
Andrew Phillips, associated with Enliven Therapeutics, Inc. (ELVN), has filed a Form 144 to sell 26,035 shares of Common Stock acquired through a stock option exercise on March 31, 2026. This filing also discloses previous sales of 21,844 shares on February 2, 2026, and 1,520 shares on January 22, 2026. The proposed sale is valued at $1,003,610.20 and will be executed through Morgan Stanley Smith Barney LLC.
Enliven Therapeutics CMO Executes $1.2M Stock Sale | Company Update 2026 - News and Statistics
Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics, recently sold 40,000 shares of the company's common stock, generating approximately $1.2 million, after exercising options. She still holds 25,000 shares directly and a considerable number of stock options. Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on cancer therapies, currently conducting Phase 1 trials for two kinase inhibitor candidates, and reported a net loss over the past year.
Price-Driven Insight from (ELVN) for Rule-Based Strategy
This article provides a price-driven analysis of Enliven Therapeutics Inc. (NASDAQ: ELVN) for rule-based trading strategies, highlighting strong sentiment across all time horizons supporting an overweight bias. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and AI-generated support/resistance levels.
Enliven (NASDAQ: ELVN) CMO exercises options and sells 40K shares
Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics (NASDAQ: ELVN), exercised options for 40,000 shares at $2.48 each and subsequently sold all 40,000 shares at a weighted average price of $35.1006. These transactions were pre-scheduled under a Rule 10b5-1 trading plan adopted in October 2025. Following these sales, Collins directly holds 25,000 shares and maintains 136,268 equity awards.
Enliven Therapeutics Insider Sold Shares Worth $1,404,024, According to a Recent SEC Filing
An insider at Enliven Therapeutics (ELVN) recently sold company shares valued at $1,404,024, as disclosed in a new SEC filing. This transaction occurred on March 27, 2026. The article also notes other recent insider sales and analyst activity, including Mizuho raising its price target for Enliven Therapeutics to $45.
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Terns Pharmaceuticals (TERN)
The article highlights bullish sentiments from financial analysts on several healthcare stocks, including Enliven Therapeutics (ELVN), Terns Pharmaceuticals (TERN), and Ionis Pharmaceuticals (IONS). Analysts from LifeSci Capital, Mizuho Securities, and TD Cowen have issued Buy ratings with specific price targets, anticipating significant upside potential for these companies based on their current stock performance and market consensus.
ELVN Stock Soars as Merck’s Billion-Dollar Acquisition Validates Strategy
Enliven Therapeutics Inc. (ELVN) stock surged by 13.99% following promising developments and FDA designations for its ELVN-001 candidate. The market's positive reaction is further fueled by Merck's acquisition of Terns Pharmaceuticals, which validates the chronic myeloid leukemia market and highlights the potential of Enliven's drug. Despite a recent quarterly loss, Enliven maintains a strong cash position, and analysts like Mizuho have raised price targets, indicating confidence in its growth prospects.
Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High on Analyst Upgrade
Enliven Therapeutics (NASDAQ:ELVN) shares reached a new 52-week high after Mizuho raised its price target from $41.00 to $45.00, maintaining an outperform rating. Despite insider selling totaling approximately $6.22 million over the last 90 days, insiders still hold about 25.9% of the company. The clinical-stage biotech, with a $2.12 billion market cap, recently missed quarterly EPS estimates but holds a MarketBeat consensus rating of "Moderate Buy" with an average price target of $41.80.
Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’
Enliven Therapeutics (ELVN) reached a five-year high after analysts provided optimistic coverage, including Mizuho raising its price target to $45 and Clear Street reiterating a "buy" rating. The stock's rally was also boosted by Merck's acquisition of a competitor, highlighting potential in the chronic myeloid leukemia (CML) market, where Enliven is developing its ELVN-001 treatment.
Enliven Therapeutics (ELVN) affiliate files to sell 45,000 shares via Jefferies
An affiliate of Enliven Therapeutics (ELVN) has filed a Section 144 notice to sell 45,000 shares of common stock through Jefferies LLC, valued at $1,401,750. The filing also disclosed previous sales by Helen Collins amounting to 45,000, 29,871, 10,129, and 5,000 shares on various dates in February and March 2026. Analysts assessed the filing with neutral impact and sentiment, noting the ongoing disposition of shares by an affiliate.
Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio
Shares of Enliven Therapeutics Inc (ELVN) rallied after Merck's $6.7 billion acquisition of Terns Pharmaceuticals' (TERN) TERN-701 highlighted the unmet need for effective chronic myeloid leukemia (CML) therapies. Clear Street sees Enliven's ELVN-001 as a high-potential, best-in-class therapy with multiple strategic paths to value, and its late-stage ENABLE-2 trial is on track for initiation in the second half of 2026. This acquisition also suggests growing interest in CML therapies beyond Novartis, opening potential opportunities for Enliven.
Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $45.00
Mizuho has increased its price target for Enliven Therapeutics (NASDAQ:ELVN) from $41.00 to $45.00, maintaining an "outperform" rating and suggesting a roughly 27% upside. This comes despite the company missing quarterly EPS estimates and recent insider selling activity. Shares of ELVN saw a significant 13.8% surge following the report.
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up After Analyst Upgrade
Enliven Therapeutics (NASDAQ:ELVN) shares gapped up after Mizuho raised its price target from $41 to $45, reiterating an "outperform" rating. Despite the positive analyst upgrade, the company recently missed its quarterly EPS estimates, and insiders have sold a significant number of shares. Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies for cancer.
Mizuho raises Enliven Therapeutics price target to $45 on CML data
Mizuho has increased its price target for Enliven Therapeutics (NASDAQ:ELVN) stock to $45 from $41, maintaining an Outperform rating, based on recent positive Phase 1b data for ELVN-001 in chronic myeloid leukemia (CML). The company plans to initiate a registrational trial for ELVN-001 in the second half of 2026 and recently announced strong Phase 1b clinical trial results, including a 69% major molecular response rate at 24 weeks. Enliven also appointed Scott Garland to its Board of Directors to bring commercial leadership experience.
Mizuho raises Enliven Therapeutics price target to $45 on CML data
Mizuho increased its price target for Enliven Therapeutics (NASDAQ:ELVN) shares to $45 from $41, maintaining an Outperform rating, based on positive Phase 1b data for ELVN-001 in chronic myeloid leukemia (CML). The company plans to initiate a registrational trial, ENABLE-2, this year for ELVN-001, which showed a 69% major molecular response rate by 24 weeks in its Phase 1b trial. Enliven also appointed Scott Garland to its Board of Directors to replace Andrew Phillips, Ph.D.
Enliven Therapeutics (Nasdaq: ELVN) founder files Form 144 to sell 100,000
Enliven Therapeutics (Nasdaq: ELVN) has filed a Form 144 indicating a proposed sale of 100,000 common founder shares by a founder through Jefferies LLC, intended for March 24, 2026, on Nasdaq. The filing also disclosed a prior insider sale by Anish Patel of 48,300 shares on January 9, 2026, for over $1.35 million. This notice signifies a planned resale and not a capital raise by the company.
Enliven Therapeutics stock hits 52-week high at $30.98 By Investing.com
Enliven Therapeutics (ELVN) shares reached a new 52-week high of $31.12, reflecting a 77% year-to-date return and strong investor confidence. The company's focus on innovative therapeutic solutions, particularly promising Phase 1b clinical trial results for ELVN-001 in chronic myeloid leukemia, and the appointment of Scott Garland to its Board of Directors, are driving this robust performance. Despite analyst "strong buy" ratings, InvestingPro data suggests the stock might be overvalued at its current levels.
Enliven Therapeutics stock hits 52-week high at $30.98 By Investing.com
Enliven Therapeutics (ELVN) shares have reached a new 52-week high of $31.12, reflecting strong market confidence and investor interest with a 77% year-to-date return. Analysts maintain a "strong buy" consensus, despite InvestingPro suggesting the stock may be overvalued. The company's financial flexibility, strong pipeline with promising Phase 1b clinical trial results for ELVN-001 in CML, and recent board appointment are key drivers of its performance.
Enliven Therapeutics (NASDAQ:ELVN) Trading 5.3% Higher - Here's What Happened
Enliven Therapeutics (NASDAQ:ELVN) saw its shares rise by 5.3% during mid-day trading on Thursday, reaching $28.685 with approximately 1.01 million shares traded. The company holds a "Moderate Buy" rating from analysts with a consensus price target of $41, despite recently missing EPS expectations and insiders being net sellers of the stock. Institutional investors, however, reportedly own about 95% of the company's shares.
(ELVN) Price Dynamics and Execution-Aware Positioning
Enliven Therapeutics Inc. (NASDAQ: ELVN) shows a mid-channel oscillation pattern with exceptional risk-reward potential, targeting an 18.1% gain. While near-term sentiment is weak, long-term indicators suggest strength, leading to divergent sentiment across different time horizons. The AI analysis provides three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for various risk profiles.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Enliven Therapeutics, Inc. (NASDAQ:ELVN) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $41.00. The company's stock shows its 50-day moving average at $27.20 and a 200-day moving average at $22.31, reflecting recent stock performance. Insider selling activity was also noted, with directors selling shares totaling over $2.7 million in recent transactions.
Enliven Therapeutics, Inc. $ELVN Shares Bought by HighVista Strategies LLC
HighVista Strategies LLC significantly increased its stake in Enliven Therapeutics (NASDAQ:ELVN), purchasing 117,619 additional shares in Q3 to hold a total of 259,135 shares valued at approximately $5.3 million. Despite recent insider selling totaling $6.3 million, insiders still own 25.90% of the company. Enliven Therapeutics, a clinical-stage biotechnology company developing small-molecule therapies for cancer, currently has a "Moderate Buy" consensus rating from analysts with a target price of $41.00, although it recently missed EPS estimates.
CFO of Enliven (NASDAQ: ELVN) sells 10,000 common shares
Enliven Therapeutics' CFO, Benjamin Hohl, sold 10,000 shares of common stock on March 6, 2026, at a weighted-average price of $29.5839 per share, as reported in a Form 4 SEC filing. Following this transaction, Hohl directly owns 51,000 shares. The sale was executed in multiple trades within a price range of $29.43 to $29.7867.
Enliven Therapeutics (ELVN) CMO sells 40,000 shares after option exercise
Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised stock options for 40,000 shares at $2.48 per share and subsequently sold all 40,000 shares in open-market trades at weighted average prices around $30. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established in October 2025. Following these sales, Collins directly holds 25,000 shares of Enliven Therapeutics Common Stock.
Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 10,000 Shares of Stock
Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl sold 10,000 shares of the company's stock on March 6th for a total of $295,800, reducing his stake by 16.39%. This transaction follows the company's recent earnings miss, reporting ($0.48) EPS against an estimated ($0.42). Despite mixed analyst ratings, with an average "Moderate Buy" and a consensus target price of $41.00, institutional ownership remains high at 95.08%.
Enliven Therapeutics (ELVN) Form 144: Director sales total 45,000 shares
Enliven Therapeutics (ELVN) has filed a Form 144, indicating proposed resale transactions for common stock totaling 45,000 shares through Jefferies LLC, with an aggregate value of $1,324,800. The filing also details two recent sales by Helen Collins on February 17, 2026, comprising 5,000 shares for $130,878.30 and 40,000 shares for $1,046,985.20. These are routine disclosures for planned and recorded dispositions of shares.
TD Asset Management Inc Sells 39,388 Shares of Enliven Therapeutics, Inc. $ELVN
TD Asset Management Inc. reduced its stake in Enliven Therapeutics (NASDAQ:ELVN) by 58.9%, selling 39,388 shares and now holding 27,518 shares valued at $563,000. Institutional investors collectively own about 95.08% of the company, while insiders have sold a significant number of shares, totaling approximately $6.15 million over the past three months, though they still retain 25.90% ownership. Analysts have a consensus "Moderate Buy" rating with an average target price of $41.00, despite some recent downgrades and the company missing its last quarterly EPS estimates.
(ELVN) as a Liquidity Pulse for Institutional Tactics
This article analyzes Enliven Therapeutics Inc. (NASDAQ: ELVN) using AI models to suggest trading strategies. It highlights a near-term neutral sentiment amidst mid and long-term strength, with elevated downside risk due to a lack of additional long-term support signals. The analysis provides distinct trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis for institutional tactics.
Enliven Therapeutics has cash runway into 2029
Enliven Therapeutics Inc., a clinical-stage precision oncology company, reported having $462.6 million in cash and equivalents at the end of 2025, which is projected to fund operations until the first half of 2029. The company's financial strength was boosted by a $230 million stock sale last year. Enliven is progressing with clinical trials, including positive results for its CML drug candidate ELVN-001, and plans for a Phase 3 pivotal trial in 2026.
Enliven Therapeutics (NASDAQ: ELVN) touts ELVN-001 data and $462.6M cash runway
Enliven Therapeutics reported positive Phase 1b data for its lead CML candidate, ELVN-001, demonstrating meaningful major molecular response rates despite patients being heavily pretreated. The company plans to initiate a pivotal Phase 3 trial in the second half of 2026 and expects its $462.6 million cash reserve to fund operations into the first half of 2029. Leadership changes were also announced to support the transition to late-stage development.
[144] Enliven Therapeutics, Inc. SEC Filing
This article details an SEC Form 144 filing by Enliven Therapeutics, Inc. (ELVN). The filing indicates a proposed sale of 10,000 shares of common stock with an aggregate market value of $292,900.00 by a person who acquired them on December 13, 2024, through the exercise of options.
ELVN Financials: Income Statement, Balance Sheet & Cash Flow
This article provides full financial statements for Enliven Therapeutics Inc (ELVN), including income statements, balance sheets, and cash flow statements, updated as of March 3, 2026. It highlights key financial metrics such as EBITDA, free cash flow, net income, and EPS for fiscal year 2025, and evaluates the company's financial health using the Piotroski F-Score and earnings quality ratio. The company currently shows weak financial health with negative profitability metrics despite a healthy current ratio.
Enliven Therapeutics (stock code: ELVN) recently released its financial report for the fourth quarter and full year of fiscal 2025, while also updating the market on the company's latest business developments.
Enliven Therapeutics (ELVN) has released its financial report for the fourth quarter and full fiscal year of 2025. The report includes key financial indicators, R&D pipeline progress, and strategic partnerships, offering a thorough overview of the company's operations for investors. The content of the article is solely the author's opinion and is not investment advice.
CML drug ELVN-001 posts positive data as Enliven banks $463M
Enliven Therapeutics announced positive initial Phase 1b data for its CML drug ELVN-001, showing Major Molecular Response (MMR) rates of up to 69% in heavily pretreated patients. The company plans to initiate a pivotal Phase 3 trial (ENABLE-2) in the second half of 2026 and reported a strong cash position of $462.6 million, expected to fund operations into the first half of 2029 despite a net loss in 2025.
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Enliven Therapeutics reported its third-quarter 2025 financial results, highlighting progress in the ELVN-001 clinical trial for CML and a strong cash position of $477.6 million, expected to last into the first half of 2029. The company completed enrollment for the randomized Phase 1b cohorts of the ENABLE trial and remains on track to initiate a Phase 3 pivotal trial for ELVN-001 in 2026. The therapy, ELVN-001, is a potent and selective small molecule kinase inhibitor targeting the BCR::ABL gene fusion, including the T315I mutation.
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Enliven Therapeutics reported its financial results for the fourth quarter and full year 2025, alongside a business update highlighting positive initial Phase 1b data for ELVN-001 in chronic myeloid leukemia (CML) patients. The company plans to initiate the Phase 3 ENABLE-2 pivotal trial for ELVN-001 in the second half of 2026, anticipating significant regulatory and operational milestones. Enliven maintains a strong financial position with $462.6 million in cash, expected to fund operations into the first half of 2029.
ELVN SEC Filings - Enliven Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors and traders to access Enliven Therapeutics Inc. (ELVN) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider trading forms (Form 4). It highlights recent insider sales by the CEO and CSO, detailing the number of shares sold, prices, and beneficial ownership after transactions, often under Rule 10b5-1 trading plans. The platform also offers AI-powered summaries to help interpret these complex regulatory disclosures.
Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded Enliven Therapeutics (NASDAQ:ELVN) from a "hold" to a "sell" rating, with Weiss Ratings also reaffirming a "sell." Despite this, MarketBeat's consensus remains a "Moderate Buy" with a $41 target price. The article notes significant insider selling, with COO Anish Patel selling 48,300 shares and other insiders selling over $6 million worth of shares in the last 90 days.
Biotech fireside chat: Enliven Therapeutics at TD Cowen event
Enliven Therapeutics (Nasdaq: ELVN) announced its management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 10:30 a.m. ET. The event will be webcast live and archived for 90 days, providing investors with updates on the company's progress, including its CML program and strong cash position. Following this news, ELVN stock saw a mild positive market reaction, gaining 1.16%.
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Enliven Therapeutics, Inc. (Nasdaq: ELVN), a clinical-stage biopharmaceutical company, announced that its management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference. The event is scheduled for Tuesday, March 3, 2026, at 10:30 a.m. ET and will be webcast live on the company's investor relations website. Enliven focuses on discovering and developing small molecule therapeutics using a precision medicine approach.
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Enliven Therapeutics, Inc. announced that its management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 10:30 a.m. ET. The event will be webcast live and archived on the company's investor relations website. Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics.
Plan-based 1,230-share sale by Enliven (ELVN) director disclosed
Enliven Therapeutics director Richard A. Heyman reported an open-market sale of 1,230 shares of common stock at a weighted average price of $26.1759 per share. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024. Following the transaction, Heyman holds 123,673 shares directly, with additional indirect holdings through various trust accounts.
Enliven Therapeutics (ELVN) director granted 17,126 stock options as award
Enliven Therapeutics (ELVN) director Jake Bauer was granted 17,126 stock options as a new equity award, with an exercise price of $0.00 per share. These options will vest 100% on the earlier of the first anniversary of the 2026 annual stockholder meeting or the 2027 annual stockholder meeting date, provided he continues as a non-employee director. This transaction is categorized as an acquisition of derivative securities and was reported in an SEC Form 4 filing on February 17, 2026.
[SCHEDULE 13G] Enliven Therapeutics, Inc. Passive Investment Disclosure (>5%)
Vestal Point Capital and its CIO Ryan Wilder have disclosed a passive investment in Enliven Therapeutics, Inc., acquiring 3,830,000 shares of common stock, which represents a 6.5% beneficial ownership stake. This investment grants them shared voting and dispositive power, with the shares held in the ordinary course of business and not intended to influence control of the company. The ownership percentage is based on 59,347,317 Enliven shares outstanding as of October 31, 2025.
Enliven director granted option for 17,126 shares | ELVN SEC Filing - Form 4
Enliven Therapeutics director Lori Anne Kunkel was granted a stock option for 17,126 shares, as reported in a Form 4 SEC filing on February 17, 2026. This derivative security grant is directly held and vests entirely on the earlier of the first anniversary of the 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting, contingent on her continued service as a non-employee director. The transaction indicates a neutral impact and sentiment according to the filing analysis.
45,000 Enliven Therapeutics (NASDAQ: ELVN) shares set for sale
Enliven Therapeutics has filed a notice of proposed insider sales under Rule 144, indicating that 45,000 shares of common stock, valued at $1,202,400.00, are set to be sold through Jefferies LLC on or about February 17, 2026, on the NASDAQ exchange. These shares were acquired via stock options on August 9, 2022, and the filing notes that 59,000,000 shares of common stock are outstanding. The seller has indicated no awareness of undisclosed material adverse information about the company.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of "Moderate Buy" by Brokerages
Enliven Therapeutics (NASDAQ:ELVN) has received an average "Moderate Buy" rating from five brokerages, with four "buy" ratings and one "sell" rating, alongside a one-year average price target of $41.00. Insider activity shows COO Anish Patel and Director Richard A. Heyman selling shares, though insiders still own 25.90% of the company. Institutional investors, including Vestal Point Capital and Vanguard Group, hold 95.08% of the stock and have been increasing their positions.
Enliven Therapeutics (NASDAQ:ELVN) Director Sells $32,201.40 in Stock
Enliven Therapeutics Director Richard Heyman sold 1,230 shares of ELVN stock on February 17th for a total of $32,201.40, reducing his position by 5.15%. The company's stock currently trades around $26.16, with a market cap of $1.55 billion and significant institutional ownership at 95.08%. Analysts maintain a "Moderate Buy" rating with a target price of $41.00.
